Methods and compositions of predicting activity of retinoid X receptor modulator
US10202652B2 · kind B2 · utility
0Cited by
1References
18Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 7, 2012 |
| Grant date | Feb 12, 2019 |
| Priority date | — |
| Expiry date | Nov 7, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention describes genomic biomarkers that have been discovered to correlate with varied individual responses (efficacy, adverse effect, and other end points) to therapeutic retinoid X receptor modulator, such as bexarotene, in treating diseases such as, non small cell lung cancer. The newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which can help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might have adverse effects, by the treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.